Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil TV Ad Case Could Produce Ruling On FDA’s Authority To Regulate Ads

Executive Summary

A suit regarding claims in Paxil TV ads could produce a court ruling regarding FDA's authority to regulate advertising

You may also be interested in...



Paxil product liability claims

GlaxoSmithKline has settled more than 90% of the product liability claims against Paxil (paroxetine) related to discontinuation symptoms. As part of the settlements, "most" of the pending class action suits concerning discontinuation symptoms are being dismissed, firm says. GSK maintains it did not "admit liability with respect to the allegations in any of the suits." Paxil's labeling was revised in December 2002 to include a precaution concerning "discontinuation of treatment" (1"The Pink Sheet" Aug. 22, 2002, p. 21)...

Paxil product liability claims

GlaxoSmithKline has settled more than 90% of the product liability claims against Paxil (paroxetine) related to discontinuation symptoms. As part of the settlements, "most" of the pending class action suits concerning discontinuation symptoms are being dismissed, firm says. GSK maintains it did not "admit liability with respect to the allegations in any of the suits." Paxil's labeling was revised in December 2002 to include a precaution concerning "discontinuation of treatment" (1"The Pink Sheet" Aug. 22, 2002, p. 21)...

GSK Paxil CR Ad Medicalizes “Ordinary” Anxiety, FDA Says

GlaxoSmithKline Paxil CR TV ads suggest the antidepressant is appropriate for treating anxiety that does not require medication, FDA's ad division says

Related Content

UsernamePublicRestriction

Register

PS040381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel